

SB 872

Relating to the cost of prescription drugs

SB 872 implements recommendations from the Task Force on Fair Pricing of Prescription Drugs, which was established in 2018 to develop strategies to create transparency for prescription prices in Oregon. With the changes recommended by the Subcommittee, the measure establishes distinct requirements for the reporting and disclosure of prescription drug pricing and other information from medical providers, health insurers, pharmaceutical manufacturers, pharmacy benefit managers, and patient advocacy groups.

The measure also requires state-sponsored health plans to contract on a fee-only basis with pharmacy benefit managers, which are required to pass through any rebates, incentives, or discounts offered by manufacturers. The measure establishes drug expenditure reporting requirements for state agencies and requires the Pharmacy and Therapeutics Committee to evaluate drug expenditures and make recommendations regarding the inclusion of drugs on any preferred drug list adopted by the Oregon Health Authority.

The recommendation appropriates \$390,534 General Fund to OHA to cover the estimated fiscal impact.

The Capital Construction Subcommittee recommends SB 872 be amended by the -12 amendment and be reported out do pass, as amended.